Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 guselkumab trial in perianal fistulizing Crohn's disease
MOH_2022-09-07_012030Phase 3Not yet recruiting
- Sponsor
- Johnson & Johnson
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of guselkumab in Crohn's disease and anal fistula (3 arms), sponsored by Johnson & Johnson. Primary endpoint: Efficacy and safety of guselkumab. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
guselkumab
03
Conditions
Crohn's diseaseanal fistula
Beyond the preview
Go deeper on MOH_2022-09-07_012030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-09-07_012030.